IPP Bureau
Cepheid launches its first manufacturing unit in India
By IPP Bureau - March 15, 2023
The facility has been set up to manufacture tuberculosis testing cartridges
Philips and Gibraltar Health Authority announce 16-year strategic partnership
By IPP Bureau - March 15, 2023
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
LifeSigns raises Pre-Series A
By IPP Bureau - March 15, 2023
A funding to expand operations and provide better patient care
Pfizer acquires Seagen for US$ 43 billion to battle cancer
By IPP Bureau - March 14, 2023
Proposed combination enhances Pfizer’s position as a leading company in oncology
Briefs: Lupin and Alembic
By IPP Bureau - March 14, 2023
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
Dr. Lal PathLabs selects Kyndryl for cloud services management
By IPP Bureau - March 14, 2023
Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces
Alpla and Inden pharma form joint venture
By IPP Bureau - March 14, 2023
ALPLA is expanding its presence in the global market for pharmaceutical packaging by establishing a joint venture with Inden Pharma
Precision appoints John Hubbard, PhD, as Board of Directors Chair
By IPP Bureau - March 14, 2023
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
By IPP Bureau - March 13, 2023
The company will be submitting the responses to US FDA observations within stipulated timeline
Zydus receives final approval from the USFDA for Olanzapine
By IPP Bureau - March 13, 2023
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
Agilent announces digital pathology workflow solution
By IPP Bureau - March 13, 2023
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
Keytruda + chemotherapy improved overall survival versus chemotherapy alone as for advanced malignant pleural mesothelioma
By IPP Bureau - March 12, 2023
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Marksans Pharma announces USFDA approval for Famotidine Tablets
By IPP Bureau - March 11, 2023
Marksans' OTC Famotidine Tablets USP are acid reducers
USFDA completes inspection of Lupin’s Vizag facility
By IPP Bureau - March 11, 2023
The inspection concluded with no observations
Baxter launches the 'Choose Freedom' campaign for kidney disease patients
By IPP Bureau - March 11, 2023
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
